Noveome Biotherapeutics, Inc. Completes $15 Million Series D Financing to Advance Growing Pipeline of Next-Generation Biologics PITTSBURGH, April 9, 2019-- Noveome Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues, today announced the closing of a $15 million Series D financing. The financing was led by a new institutional investor in addition to existing investors.